A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells.

Most adult humans are infected benignly and for life with the herpesvirus Epstein-Barr virus. EBV has been a focus of research because of its status as a candidate tumor virus for a number of lymphomas and carcinomas. In vitro EBV has the ability to establish a latent infection in proliferating B lymphoblasts. This is the only system available for studying human herpesvirus latency in culture and has been extremely useful for elucidating how EBV promotes cellular growth. However, to understand how EBV survives in the healthy host and what goes awry, leading to disease, it is essential to know how EBV establishes and maintains a persistent infection in vivo. Early studies on the mechanism of EBV persistence produced inconclusive and often contradictory results because the techniques available were crude and insensitive. Recent advances in PCR technology and the application of sophisticated cell fractionation techniques have now provided new insights into the behavior of the virus. Most dramatically it has been shown that EBV in vivo does not establish latency in a proliferating lymphoblast, but in a resting memory B cell. The contrasting behaviors of being able to establish a latent infection in proliferating B blasts and resting memory B cells can be resolved in terms of a model where EBV performs its complete life cycle in B lymphocytes. The virus achieves this not by disrupting normal B cell biology but by using it.

[1]  J. Banchereau,et al.  Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A , 1992, The Journal of experimental medicine.

[2]  D. Thorley-Lawson,et al.  EBV persistence in memory B cells in vivo. , 1998, Immunity.

[3]  R. Schooley,et al.  BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. , 1985, Journal of immunology.

[4]  I. Maclennan,et al.  A subset of CD4+ memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex , 1995, The Journal of experimental medicine.

[5]  E. Reddy,et al.  Transducers of life and death: TNF receptor superfamily and associated proteins. , 1996, Oncogene.

[6]  A. Levine,et al.  Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6 , 1990, Cell.

[7]  N. Ling,et al.  B cell proliferation in follicles, germinal centre formation and the site of neoplastic transformation in Burkitt's lymphoma. , 1988, Current topics in microbiology and immunology.

[8]  Gwyn T. Williams,et al.  Activation of Epstein–Barr virus latent genes protects human B cells from death by apoptosis , 1991, Nature.

[9]  D. Gray,et al.  T cell memory is short-lived in the absence of antigen , 1988, Nature.

[10]  E. Kremmer,et al.  The Epstein‐Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis‐element of the terminal protein 1 gene promoter. , 1993, The EMBO journal.

[11]  Qingxue Li,et al.  Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes , 1997, Journal of virology.

[12]  D. Thorley-Lawson,et al.  Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo , 1982, Journal of virology.

[13]  J. Banchereau,et al.  The CD40 antigen and its ligand. , 1994, Annual review of immunology.

[14]  D. Thorley-Lawson,et al.  All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts , 1993, Journal of virology.

[15]  K. Rajewsky,et al.  Maintenance of B-cell memory by long-lived cells generated from proliferating precursors , 1990, Nature.

[16]  N. Raab-Traub,et al.  Epstein-Barr virus replication in oropharyngeal epithelial cells. , 1984, The New England journal of medicine.

[17]  E. Cesarman,et al.  Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. , 1995, Blood.

[18]  D. Thorley-Lawson,et al.  Early events in Epstein-Barr virus infection provide a model for B cell activation , 1985, The Journal of experimental medicine.

[19]  W. Hammerschmidt,et al.  Genetic analysis of immortalizing functions of Epstein–Barr virus in human B lymphocytes , 1989, Nature.

[20]  H. Cen,et al.  EBV gene expression, EBNA antibody responses and EBV+ peripheral blood lymphocytes in post-transplant lymphoproliferative disease. , 1994, Leukemia & lymphoma.

[21]  P. L. Deininger,et al.  DNA sequence and expression of the B95-8 Epstein—Barr virus genome , 1984, Nature.

[22]  A. Rickinson Virology: Epstein–Barr virus in epithelium , 1984, Nature.

[23]  C. Arpin,et al.  Germinal center development , 1997, Immunological reviews.

[24]  G. Peters,et al.  EBNA‐2 and EBNA‐LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein‐Barr virus. , 1994, The EMBO journal.

[25]  R. Osamura,et al.  Reticular crypt epithelium and intra‐epithelial lymphoid cells in the hyperplastic human palatine tonsil: An immunohistochemical analysis , 1995, Pathology international.

[26]  J. Hsieh,et al.  EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1 , 1994, Journal of virology.

[27]  J. Burrows,et al.  Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift , 1997, Journal of virology.

[28]  L. Young,et al.  Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells , 1993, The Journal of experimental medicine.

[29]  L. Lanier,et al.  CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes , 1992, The Journal of experimental medicine.

[30]  E. Kieff,et al.  Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein , 1984, Journal of virology.

[31]  G. Klein Viral latency and transformation: The strategy of Epstein-Barr virus , 1989, Cell.

[32]  Stefan Imreh,et al.  Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1 , 1995, Nature.

[33]  C. Ware,et al.  The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family , 1995, Cell.

[34]  D. Thorley-Lawson,et al.  Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals , 1996, Journal of virology.

[35]  J. Hsieh,et al.  Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2 , 1996, Molecular and cellular biology.

[36]  E. Kremmer,et al.  B‐cell proliferation and induction of early G1‐regulating proteins by Epstein‐Barr virus mutants conditional for EBNA2. , 1995, The EMBO journal.

[37]  J. Sample,et al.  Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein , 1996, Journal of virology.

[38]  V. Baichwal,et al.  Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. , 1988, Oncogene.

[39]  W. Hammerschmidt,et al.  Epstein–Barr virus‐mediated B‐cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor , 1998, The EMBO journal.

[40]  G. Nemerow,et al.  Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2) , 1985, Journal of virology.

[41]  J. Salisbury,et al.  Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells , 1997, Oncogene.

[42]  J. Yates,et al.  Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells , 1985, Nature.

[43]  J. Pagano,et al.  Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor , 1994, Molecular and cellular biology.

[44]  D. Rowe,et al.  Epstein-Barr virus latent messages with shuffled leader exons: remnants of circumgenomic transcription? , 1995, Journal of virology.

[45]  M. Sandberg,et al.  Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3 , 1997, Journal of virology.

[46]  H. Stein,et al.  Strict lymphotropism of Epstein-Barr virus during acute infectious mononucleosis in nonimmunocompromised individuals. , 1997, Blood.

[47]  R. Schooley,et al.  Epstein-Barr virus superinduces a new human b cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts , 1982, Cell.

[48]  H. Stein,et al.  Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. , 1995, Blood.

[49]  J. Banchereau,et al.  Five human mature B cell subsets. , 1994, Advances in experimental medicine and biology.

[50]  D. Thorley-Lawson,et al.  Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell , 1997 .

[51]  T. Crook,et al.  Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. , 1996, Oncogene.

[52]  J. Banchereau,et al.  Germinal Center Founder Cells Display Propensity for Apoptosis before Onset of Somatic Mutation , 1997, The Journal of experimental medicine.

[53]  Q Y Yao,et al.  Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts , 1992, Journal of virology.

[54]  D. Fearon,et al.  Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes , 1993, The Journal of experimental medicine.

[55]  E. Kieff,et al.  Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation , 1991, Journal of virology.

[56]  E. Kremmer,et al.  Immunohistochemical Detection of the Epstein-Barr Virus–Encoded Latent Membrane Protein 2A in Hodgkin's Disease and Infectious Mononucleosis , 1997 .

[57]  B. Griffin,et al.  Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. , 1989, The Journal of general virology.

[58]  J. Banchereau,et al.  Memory B Cells Are Biased Towards Terminal Differentiation: A Strategy That May Prevent Repertoire Freezing , 1997, The Journal of experimental medicine.

[59]  E. Lennette,et al.  Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. , 1985, The New England journal of medicine.

[60]  J. Banchereau,et al.  Human germinal center B cells express the apoptosis-inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2 , 1996, The Journal of experimental medicine.

[61]  E. Kieff,et al.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23 , 1990, Journal of virology.

[62]  D. Rowe,et al.  Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes , 1992, Journal of virology.

[63]  D. Baltimore,et al.  Localization of the Major NF-κB-activating Site and the Sole TRAF3 Binding Site of LMP-1 Defines Two Distinct Signaling Motifs* , 1997, The Journal of Biological Chemistry.

[64]  M. Ueffing,et al.  Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule , 1997, The EMBO journal.

[65]  M. Hammarskjöld,et al.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity , 1992, Journal of virology.

[66]  K. Rajewsky,et al.  Human Immunoglobulin (Ig)M+IgD+ Peripheral Blood B Cells Expressing the CD27 Cell Surface Antigen Carry Somatically Mutated Variable Region Genes: CD27 as a General Marker for Somatically Mutated (Memory) B Cells , 1998, The Journal of experimental medicine.

[67]  D. Gray,et al.  B‐T Lymphocyte Interactions in the Generation and Survival of Memory Cells , 1996, Immunological reviews.

[68]  D. Thorley-Lawson,et al.  Is EBV persistence in vivo a model for B cell homeostasis? , 1996, Immunity.

[69]  E. Kieff,et al.  The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro , 1993, Journal of virology.

[70]  W. Kolch,et al.  Epstein–Barr virus latent membrane protein‐1 triggers AP‐1 activity via the c‐Jun N‐terminal kinase cascade , 1997, The EMBO journal.

[71]  K. Rajewsky,et al.  The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. , 1998, Annual review of immunology.

[72]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[73]  K. Rajewsky,et al.  In Vivo Ablation of Surface Immunoglobulin on Mature B Cells by Inducible Gene Targeting Results in Rapid Cell Death , 1997, Cell.

[74]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.

[75]  K. Rajewsky,et al.  Evidence for a large compartment of IgM-expressing memory B cells in humans. , 1997, Blood.

[76]  J. Spencer,et al.  Human marginal-zone B cells. , 1998, Immunology today.

[77]  S. T. Liu,et al.  Identification of a novel promoter located within the Bam HI Q region of the Epstein-Barr virus genome for the EBNA 1 gene. , 1995, DNA and cell biology.

[78]  Kenji Matsuno,et al.  Notch signaling. , 1995, Science.

[79]  D. Choquet,et al.  The (YXXL/I)2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein‐Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation events. , 1993, The EMBO journal.

[80]  G. Nemerow,et al.  Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2) , 1989, Cell.

[81]  M. Perricaudet,et al.  A spliced Epstein‐Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. , 1988, The EMBO journal.

[82]  I. Ernberg,et al.  Epstein-Barr virus: adaptation to a life within the immune system. , 1994, Trends in microbiology.

[83]  E. Kieff,et al.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells , 1985, Cell.

[84]  J. Banchereau,et al.  Generation of memory B cells and plasma cells in vitro , 1995, Science.

[85]  S. Speck,et al.  Alternative splicing dictates translational start in Epstein‐Barr virus transcripts. , 1990, The EMBO journal.

[86]  E. Kieff,et al.  Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. , 1995, Immunity.

[87]  E. Kieff,et al.  Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1 , 1990, Journal of virology.

[88]  C. Rooney,et al.  Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus , 1989, Journal of virology.

[89]  E. Kieff,et al.  Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development , 1992, The Journal of experimental medicine.

[90]  S. Anderson,et al.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. , 1998, Immunity.